Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Lobbying Update: $90,000 of REGENERON PHARMACEUTICALS INC. lobbying was just disclosed

None

$90,000 of REGENERON PHARMACEUTICALS INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"There is no current bill filed. Engagement with HHS regarding issues related to healthcare."

You can find more data on corporate lobbying on Quiver Quantitative.

REGN Congressional Stock Trading

Members of Congress have traded $REGN stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

REGN Insider Trading Activity

REGN Insider Trades

REGN insiders have traded $REGN stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.

Here’s a breakdown of recent trading of $REGN stock by insiders over the last 6 months:

  • CHRISTINE A POON has made 0 purchases and 6 sales selling 6,500 shares for an estimated $4,252,745.
  • JASON PITOFSKY (SVP Controller) has made 0 purchases and 12 sales selling 2,467 shares for an estimated $1,865,824.
  • BONNIE L BASSLER has made 0 purchases and 2 sales selling 2,260 shares for an estimated $1,770,000.
  • HUDA Y ZOGHBI has made 0 purchases and 11 sales selling 1,638 shares for an estimated $1,279,811.
  • ARTHUR F RYAN has made 0 purchases and 13 sales selling 100 shares for an estimated $77,852.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

REGN Hedge Fund Activity

We have seen 669 institutional investors add shares of REGN stock to their portfolio, and 581 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

REGN Analyst Ratings

Wall Street analysts have issued reports on $REGN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Truist Securities issued a "Buy" rating on 02/02/2026
  • Cantor Fitzgerald issued a "Overweight" rating on 02/02/2026
  • B of A Securities issued a "Buy" rating on 01/07/2026
  • BMO Capital issued a "Outperform" rating on 12/04/2025
  • HSBC issued a "Buy" rating on 11/24/2025
  • Citigroup issued a "Buy" rating on 10/29/2025
  • Guggenheim issued a "Buy" rating on 10/29/2025

To track analyst ratings and price targets for REGN, check out Quiver Quantitative's $REGN forecast page.

REGN Price Targets

Multiple analysts have issued price targets for $REGN recently. We have seen 19 analysts offer price targets for $REGN in the last 6 months, with a median target of $860.0.

Here are some recent targets:

  • Matthew Harrison from Morgan Stanley set a target price of $796.0 on 04/10/2026
  • William Pickering from Bernstein set a target price of $921.0 on 04/08/2026
  • Biren Amin from Piper Sandler set a target price of $875.0 on 03/31/2026
  • Gregory Renza from Truist Securities set a target price of $801.0 on 03/31/2026
  • Eliana Merle from Barclays set a target price of $923.0 on 03/06/2026
  • Brian Abrahams from RBC Capital set a target price of $765.0 on 03/02/2026
  • Yatin Suneja from Guggenheim set a target price of $975.0 on 02/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles